Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)

被引：0
|
作者：
Narendra, D. [1 ]
Baptist, A. P. [2 ]
Lee, L. [3 ]
Noorduyn, S. G. [4 ]
Liu, M. [5 ]
Igboekwe, E. E. [6 ]
Veeranki, P. [5 ]
Kahle-Wrobleski, K. [7 ]
Paczkowski, R. [3 ]
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[4] GSK, Global Value Evidence & Outcomes, Mississauga, ON, Canada
[5] Optum, Hlth Econ & Outcomes Res, Minneapolis, MN USA
[6] GSK, US Med Affairs, Raleigh, NC USA
[7] GSK, US Med Affairs, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2091
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
    Nakamura, Yoichi
    Hozawa, Soichiro
    Sagara, Hironori
    Ohbayashi, Hiroyuki
    Lee, Laurie A.
    Crawford, Jodie
    Tamaoki, Jun
    Nishi, Takanobu
    Fowler, Andrew
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1657 - 1665
  • [42] Captain Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship with Trough FEV1
    Fowler, A.
    Kerstjens, H.
    Bailes, Z.
    Tabberer, M.
    Barnes, N.
    Peachey, G.
    Oppenheimer, J.
    Lee, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [43] INTREPID: Clinical Effectiveness of ONCE-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice
    Halpin, D. M. G.
    Worsley, S.
    Afisi, I
    Astrom, J.
    Beeh, K. M.
    Brintziki, D.
    Di Boscio, V
    Kocks, J.
    Marin, J. M.
    Tabberer, M.
    Snowise, N. G.
    Compton, C.
    PNEUMOLOGIE, 2021, 75 : S42 - S43
  • [44] Intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice
    Halpin, D. M.
    Worsley, S.
    Ismaila, A. S.
    Astrom, J.
    Beeh, K. M.
    Brintziki, D.
    Di Boscio, V.
    Kocks, J.
    Marin, J. M.
    Tabberer, M.
    Snowise, N. G.
    Compton, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [45] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings
    Kaisermann, M. C.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S. J.
    Singh, D.
    Wise, R. A.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [46] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
    Criner, G. J.
    Dransfield, M.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [47] Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
    Pelaia, Corrado
    Procopio, Giada
    Deodato, Maria Rosaria
    Florio, Olivia
    Maglio, Angelantonio
    Sciacqua, Angela
    Vatrella, Alessandro
    Pelaia, Girolamo
    RESPIRATION, 2021, 100 (02) : 127 - 134
  • [48] Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [49] Evaluating the Impact and Benefits of Once Daily Fluticasone Furoate/Vilanterol (FF/VI) in Asthma and Chronic Obstructive Pulmonary Disease (COPD)
    Svedsater, H.
    Macey, J.
    Doll, H.
    Vanya, M.
    Miles, G.
    Bradshaw, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [50] Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease
    Harada, Naoko
    Otsuka, Kengo
    Horiuchi, Atsuo
    Shinka, Yoko
    Yamamura, Hiroyuki
    Miyao, Naoki
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
12345